Targeted Therapies for the Evolving Molecular Landscape of Acute Myeloid Leukemia.

Cancers (Basel) · 2021 · PMC8471378 · PMID 34572873

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

failed to reach statistical significanceno p-value reported

While intentions to reevaluate pending the release of phase III results seemed reasonable and were expected to validate fast-track approvals, phase III data for the azacitadine + LDAC combination failed to reach statistical significance for overall survival (7.2 vs. 4.1 months) [ 69 ].

also in 6,035 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.